It is noteworthy that tumours with both PTEN loss and ERG expression exhibit distinct clinical characteristics and therapeutic responses, indicating the potential of integrating these biomarkers to enhance personalised treatment strategies (6, 7). Here, PTEN is linked to neoplasm.